OPINION: Chinese Healthcare Industry Entering A ‘New Normal’?
This article was originally published in PharmAsia News
Executive Summary
Two years after the GSK scandal broke in China, a national campaign against corruption is marching on in the country, and a series of recent events suggests that Chinese authorities are determined to clean up the healthcare industry and bring in a 'new normal'. For multinational companies, the shakeup should come as welcome news, and it is time to devise strategies to prepare for a new phase of reform in the country.
You may also be interested in...
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.